Results 161 to 170 of about 27,805 (255)
Evolution of a trait distributed over a large fragmented population: propagation of chaos meets adaptive dynamics. [PDF]
Lambert A +3 more
europepmc +1 more source
Bounded variation and differentiability of functions
openaire +2 more sources
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi +9 more
wiley +1 more source
A Novel Version of the Arcsine-Rayleigh Distribution with Entropy Measures, Statistical Inference, and Applications. [PDF]
Al-Moisheer AS +3 more
europepmc +1 more source
ABSTRACT Objective We aim to comprehensively analyze how regional tumor and edema characteristics are associated with clinical presentations and survival outcomes in a large cohort of glioblastoma patients. Methods Patients with IDH‐wildtype glioblastoma who received brain MRI from 2010 to 2023 were included.
Daniel J. Zhou +16 more
wiley +1 more source
Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro +6 more
wiley +1 more source
On De Giorgi's conjecture of nonlocal approximations for free-discontinuity problems: The symmetric gradient case. [PDF]
Almi S, Davoli E, Kubin A, Tasso E.
europepmc +1 more source
On functions of generalized bounded ω-variation [PDF]
openaire +2 more sources
ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit +11 more
wiley +1 more source

